Last updated: 2026-09-23 20:47:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
TG Therapeutics, Inc. (TGTX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $55,95, with a market capitalization of $8,75B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $26,76 to $59,30. This page covers its latest market performance, valuation, price trends and company information.
$8,75B | |
$58,11 | |
$59,30 | |
$2,97 | |
$58,11 | |
1,69M | |
2,20M | |
-- | |
$59,30 | |
$26,76 | |
-- | |
-- |
TG Therapeutics, Inc. (TGTX) is trading at $55,95 in after-hours trading as of 2026-09-23 20:38:00, down 3,72% ($2,16) from the regular-session close of $58,11.
After-hours trading shows how investors are pricing TGTX after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, TG Therapeutics, Inc. (TGTX) moved from $54,00 to $55,95, representing a gain of 3,62% ($1,95).
The stock traded between $52,50 and $58,92 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 2,33 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 89,7%
TGTX is currently trading at $55,95, placing it 89,7% of the way from its 52-week low of $26,76 to its 52-week high of $59,30. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 399 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of TG Therapeutics, Inc. (TGTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.